Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy

M. Uchida, T. Nakamura, Y. Makihara, K. Suetsugu, H. Ikesue, Yasuo Mori, Koji Kato, Motoaki Shiratsuchi, K. Hosohata, Toshihiro Miyamoto, Koichi Akashi

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

The antiemetic effects and safety of granisetron and palonosetron against chemotherapy-induced nausea and vomiting (CINV) were retrospectively evaluated in patients with non-Hodgkin lymphoma receiving bendamustine-based chemotherapy. A total of 61 patients were eligible for this study. Before starting the bendamustine-based chemotherapy, granisetron or palonosetron were intravenously administered with or without aprepitant and/or dexamethasone. The proportions of patients with complete control (CC) during the overall (during the 6 days after the start of the chemotherapy), acute (up to 2 days), and delayed (3 to 6 days) phases were assessed. CC was defined as complete response with only grade 0–1 nausea, no vomiting, and no use of antiemetic rescue medication. Granisetron or palonosetron alone were administered to 9 and 19 patients, respectively. Aprepitant and/or dexamethasone were combined with granisetron and palonosetron in 28 and 5 patients, respectively. Acute CINV was completely controlled in all patients. Both granisetron monotherapy and palonosetron combination therapy could provide good control of delayed CINV, although the CC rates during the delayed and overall phases were not significantly different among mono- and combination therapy of the antiemetics. There was no significant difference in the frequencies of adverse drug events between the granisetron and palonosetron treatment groups. The present study showed that the antiemetic efficacy and safety of granisetron-based therapy were non-inferior to those of palonosetron-based therapy. Taken together with treatment costs, granisetron monotherapy would be adequate to prevent CINV in patients with non-Hodgkin lymphoma receiving bendamustine-based chemotherapy.

元の言語英語
ページ(範囲)304-308
ページ数5
ジャーナルPharmazie
73
発行部数5
DOI
出版物ステータス出版済み - 1 1 2018

Fingerprint

Granisetron
Antiemetics
Drug Therapy
Nausea
Vomiting
aprepitant
Non-Hodgkin's Lymphoma
Dexamethasone
Therapeutics
Safety
palonosetron
Bendamustine Hydrochloride
Drug-Related Side Effects and Adverse Reactions
Health Care Costs

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

これを引用

Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy. / Uchida, M.; Nakamura, T.; Makihara, Y.; Suetsugu, K.; Ikesue, H.; Mori, Yasuo; Kato, Koji; Shiratsuchi, Motoaki; Hosohata, K.; Miyamoto, Toshihiro; Akashi, Koichi.

:: Pharmazie, 巻 73, 番号 5, 01.01.2018, p. 304-308.

研究成果: ジャーナルへの寄稿記事

@article{44c75f0aa52b4a229bfee39a023b5390,
title = "Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy",
abstract = "The antiemetic effects and safety of granisetron and palonosetron against chemotherapy-induced nausea and vomiting (CINV) were retrospectively evaluated in patients with non-Hodgkin lymphoma receiving bendamustine-based chemotherapy. A total of 61 patients were eligible for this study. Before starting the bendamustine-based chemotherapy, granisetron or palonosetron were intravenously administered with or without aprepitant and/or dexamethasone. The proportions of patients with complete control (CC) during the overall (during the 6 days after the start of the chemotherapy), acute (up to 2 days), and delayed (3 to 6 days) phases were assessed. CC was defined as complete response with only grade 0–1 nausea, no vomiting, and no use of antiemetic rescue medication. Granisetron or palonosetron alone were administered to 9 and 19 patients, respectively. Aprepitant and/or dexamethasone were combined with granisetron and palonosetron in 28 and 5 patients, respectively. Acute CINV was completely controlled in all patients. Both granisetron monotherapy and palonosetron combination therapy could provide good control of delayed CINV, although the CC rates during the delayed and overall phases were not significantly different among mono- and combination therapy of the antiemetics. There was no significant difference in the frequencies of adverse drug events between the granisetron and palonosetron treatment groups. The present study showed that the antiemetic efficacy and safety of granisetron-based therapy were non-inferior to those of palonosetron-based therapy. Taken together with treatment costs, granisetron monotherapy would be adequate to prevent CINV in patients with non-Hodgkin lymphoma receiving bendamustine-based chemotherapy.",
author = "M. Uchida and T. Nakamura and Y. Makihara and K. Suetsugu and H. Ikesue and Yasuo Mori and Koji Kato and Motoaki Shiratsuchi and K. Hosohata and Toshihiro Miyamoto and Koichi Akashi",
year = "2018",
month = "1",
day = "1",
doi = "10.1691/ph.2018.7948",
language = "English",
volume = "73",
pages = "304--308",
journal = "Die Pharmazie",
issn = "0031-7144",
publisher = "Govi-Verlag Pharmazeutischer Verlag GmbH",
number = "5",

}

TY - JOUR

T1 - Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy

AU - Uchida, M.

AU - Nakamura, T.

AU - Makihara, Y.

AU - Suetsugu, K.

AU - Ikesue, H.

AU - Mori, Yasuo

AU - Kato, Koji

AU - Shiratsuchi, Motoaki

AU - Hosohata, K.

AU - Miyamoto, Toshihiro

AU - Akashi, Koichi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The antiemetic effects and safety of granisetron and palonosetron against chemotherapy-induced nausea and vomiting (CINV) were retrospectively evaluated in patients with non-Hodgkin lymphoma receiving bendamustine-based chemotherapy. A total of 61 patients were eligible for this study. Before starting the bendamustine-based chemotherapy, granisetron or palonosetron were intravenously administered with or without aprepitant and/or dexamethasone. The proportions of patients with complete control (CC) during the overall (during the 6 days after the start of the chemotherapy), acute (up to 2 days), and delayed (3 to 6 days) phases were assessed. CC was defined as complete response with only grade 0–1 nausea, no vomiting, and no use of antiemetic rescue medication. Granisetron or palonosetron alone were administered to 9 and 19 patients, respectively. Aprepitant and/or dexamethasone were combined with granisetron and palonosetron in 28 and 5 patients, respectively. Acute CINV was completely controlled in all patients. Both granisetron monotherapy and palonosetron combination therapy could provide good control of delayed CINV, although the CC rates during the delayed and overall phases were not significantly different among mono- and combination therapy of the antiemetics. There was no significant difference in the frequencies of adverse drug events between the granisetron and palonosetron treatment groups. The present study showed that the antiemetic efficacy and safety of granisetron-based therapy were non-inferior to those of palonosetron-based therapy. Taken together with treatment costs, granisetron monotherapy would be adequate to prevent CINV in patients with non-Hodgkin lymphoma receiving bendamustine-based chemotherapy.

AB - The antiemetic effects and safety of granisetron and palonosetron against chemotherapy-induced nausea and vomiting (CINV) were retrospectively evaluated in patients with non-Hodgkin lymphoma receiving bendamustine-based chemotherapy. A total of 61 patients were eligible for this study. Before starting the bendamustine-based chemotherapy, granisetron or palonosetron were intravenously administered with or without aprepitant and/or dexamethasone. The proportions of patients with complete control (CC) during the overall (during the 6 days after the start of the chemotherapy), acute (up to 2 days), and delayed (3 to 6 days) phases were assessed. CC was defined as complete response with only grade 0–1 nausea, no vomiting, and no use of antiemetic rescue medication. Granisetron or palonosetron alone were administered to 9 and 19 patients, respectively. Aprepitant and/or dexamethasone were combined with granisetron and palonosetron in 28 and 5 patients, respectively. Acute CINV was completely controlled in all patients. Both granisetron monotherapy and palonosetron combination therapy could provide good control of delayed CINV, although the CC rates during the delayed and overall phases were not significantly different among mono- and combination therapy of the antiemetics. There was no significant difference in the frequencies of adverse drug events between the granisetron and palonosetron treatment groups. The present study showed that the antiemetic efficacy and safety of granisetron-based therapy were non-inferior to those of palonosetron-based therapy. Taken together with treatment costs, granisetron monotherapy would be adequate to prevent CINV in patients with non-Hodgkin lymphoma receiving bendamustine-based chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85046669985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046669985&partnerID=8YFLogxK

U2 - 10.1691/ph.2018.7948

DO - 10.1691/ph.2018.7948

M3 - Article

C2 - 29724299

AN - SCOPUS:85046669985

VL - 73

SP - 304

EP - 308

JO - Die Pharmazie

JF - Die Pharmazie

SN - 0031-7144

IS - 5

ER -